Faruqi & Faruqi Reminds Centene Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 8, 2025 - CNC

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is reminding investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Centene [4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Company Performance and Stock Impact - Centene provided positive statements while concealing adverse facts about its enrollment and morbidity rates, leading to investor skepticism [6]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [6]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [7].